315 related articles for article (PubMed ID: 26972631)
21. Aortic-Brachial Arterial Stiffness Gradient and Cardiovascular Risk in the Community: The Framingham Heart Study.
Niiranen TJ; Kalesan B; Larson MG; Hamburg NM; Benjamin EJ; Mitchell GF; Vasan RS
Hypertension; 2017 Jun; 69(6):1022-1028. PubMed ID: 28396534
[TBL] [Abstract][Full Text] [Related]
22. Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD.
Lidgard B; Zelnickv L; Anderson AH; Feldman H; Go A; He J; Kansal M; Mohanty MJ; Mehta R; Shlipak MG; Soliman E; Weir MR; Bansal N;
Kidney360; 2022 May; 3(5):859-871. PubMed ID: 36128494
[TBL] [Abstract][Full Text] [Related]
23. Gender, High-Sensitivity Troponin I, and the Risk of Cardiovascular Events (from the Nord-Trøndelag Health Study).
Lyngbakken MN; Røsjø H; Holmen OL; Nygård S; Dalen H; Hveem K; Omland T
Am J Cardiol; 2016 Sep; 118(6):816-821. PubMed ID: 27453509
[TBL] [Abstract][Full Text] [Related]
24. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event.
Pareek M; Bhatt DL; Vaduganathan M; Biering-Sørensen T; Qamar A; Diederichsen AC; Møller JE; Hindersson P; Leósdóttir M; Magnusson M; Nilsson PM; Olsen MH
Eur J Prev Cardiol; 2017 Oct; 24(15):1648-1659. PubMed ID: 28644092
[TBL] [Abstract][Full Text] [Related]
25. Relations of Arterial Stiffness and Brachial Flow-Mediated Dilation With New-Onset Atrial Fibrillation: The Framingham Heart Study.
Shaikh AY; Wang N; Yin X; Larson MG; Vasan RS; Hamburg NM; Magnani JW; Ellinor PT; Lubitz SA; Mitchell GF; Benjamin EJ; McManus DD
Hypertension; 2016 Sep; 68(3):590-6. PubMed ID: 27456517
[TBL] [Abstract][Full Text] [Related]
26. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.
Wang TJ; Wollert KC; Larson MG; Coglianese E; McCabe EL; Cheng S; Ho JE; Fradley MG; Ghorbani A; Xanthakis V; Kempf T; Benjamin EJ; Levy D; Vasan RS; Januzzi JL
Circulation; 2012 Sep; 126(13):1596-604. PubMed ID: 22907935
[TBL] [Abstract][Full Text] [Related]
27. Multibiomarker analysis in patients with acute myocardial infarction.
Schernthaner C; Lichtenauer M; Wernly B; Paar V; Pistulli R; Rohm I; Jung C; Figulla HR; Yilmaz A; Cadamuro J; Haschke-Becher E; Pernow J; Schulze PC; Hoppe UC; Kretzschmar D
Eur J Clin Invest; 2017 Sep; 47(9):638-648. PubMed ID: 28683166
[TBL] [Abstract][Full Text] [Related]
28. Microvascular Function Contributes to the Relation Between Aortic Stiffness and Cardiovascular Events: The Framingham Heart Study.
Cooper LL; Palmisano JN; Benjamin EJ; Larson MG; Vasan RS; Mitchell GF; Hamburg NM
Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27956408
[TBL] [Abstract][Full Text] [Related]
29. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH).
Mirna M; Rohm I; Jirak P; Wernly B; Bäz L; Paar V; Kretzschmar D; Hoppe UC; Schulze PC; Lichtenauer M; Jung C; Franz M
Heart Lung Circ; 2020 Mar; 29(3):337-344. PubMed ID: 31327702
[TBL] [Abstract][Full Text] [Related]
31. Impact of diabetes on the predictive value of heart failure biomarkers.
Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
[TBL] [Abstract][Full Text] [Related]
32. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects.
Cardellini M; Rizza S; Casagrande V; Cardolini I; Ballanti M; Davato F; Porzio O; Canale MP; Legramante JM; Mavilio M; Menghini R; Martelli E; Farcomeni A; Federici M
Acta Diabetol; 2019 Mar; 56(3):273-280. PubMed ID: 30259114
[TBL] [Abstract][Full Text] [Related]
33. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of brachial and central blood pressures on circulating levels of high-sensitivity cardiac troponin I in the general population.
Sugiura T; Dohi Y; Takase H; Ito A; Fujii S; Ohte N
Atherosclerosis; 2018 Feb; 269():185-191. PubMed ID: 29366992
[TBL] [Abstract][Full Text] [Related]
35. Elevated troponin I level assessed by a new high-sensitive assay and the risk of poor outcomes in patients with acute heart failure.
Zymliński R; Sokolski M; Siwolowski P; Biegus J; Nawrocka S; Jankowska EA; Todd J; Yerramilli R; Estis J; Banasiak W; Ponikowski P
Int J Cardiol; 2017 Mar; 230():646-652. PubMed ID: 28069251
[TBL] [Abstract][Full Text] [Related]
36. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure.
Kuster N; Huet F; Dupuy AM; Akodad M; Battistella P; Agullo A; Leclercq F; Kalmanovich E; Meilhac A; Aguilhon S; Cristol JP; Roubille F
ESC Heart Fail; 2020 Oct; 7(5):2230-2239. PubMed ID: 32649062
[TBL] [Abstract][Full Text] [Related]
37. Aortic stiffness, blood pressure progression, and incident hypertension.
Kaess BM; Rong J; Larson MG; Hamburg NM; Vita JA; Levy D; Benjamin EJ; Vasan RS; Mitchell GF
JAMA; 2012 Sep; 308(9):875-81. PubMed ID: 22948697
[TBL] [Abstract][Full Text] [Related]
38. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension.
Kriechbaum SD; Wiedenroth CB; Peters K; Barde MA; Ajnwojner R; Wolter JS; Haas M; Roller FC; Guth S; Rieth AJ; Rolf A; Hamm CW; Mayer E; Keller T; Liebetrau C
Biomarkers; 2020 Nov; 25(7):578-586. PubMed ID: 32901511
[TBL] [Abstract][Full Text] [Related]
39. Variability of biomarkers in patients with chronic heart failure and healthy controls.
Meijers WC; van der Velde AR; Muller Kobold AC; Dijck-Brouwer J; Wu AH; Jaffe A; de Boer RA
Eur J Heart Fail; 2017 Mar; 19(3):357-365. PubMed ID: 27766733
[TBL] [Abstract][Full Text] [Related]
40. Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.
Jirak P; Fejzic D; Paar V; Wernly B; Pistulli R; Rohm I; Jung C; Hoppe UC; Schulze PC; Lichtenauer M; Yilmaz A; Kretzschmar D
Acta Pharmacol Sin; 2018 Jul; 39(7):1189-1196. PubMed ID: 29239349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
